William Blair & Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

William Blair & Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Buy	+7,212	New	+$179K	﹤0.01%	1499

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

William Blair & Company's RARE Position: Q2 2026 in Review

William Blair & Company opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 7,212 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #1499 among its holdings.

310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

William Blair & Company held 7,212 shares of Ultragenyx Pharmaceutical worth $241K as of Q2 2026.
Ultragenyx Pharmaceutical was a new William Blair & Company position in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1499 holding.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.